Trastuzumab Modulates the Protein Cargo of Extracellular Vesicles Released by ERBB2<sup>+</sup> Breast Cancer Cells

Cancers overexpressing the ERBB2 oncogene are aggressive and associated with a poor prognosis. Trastuzumab is an ERBB2 specific recombinant antibody employed for the treatment of these diseases since it blocks ERBB2 signaling causing growth arrest and survival inhibition. While the effects of Trastu...

Full description

Bibliographic Details
Main Authors: Silvia Marconi, Sara Santamaria, Martina Bartolucci, Sara Stigliani, Cinzia Aiello, Maria Cristina Gagliani, Grazia Bellese, Andrea Petretto, Katia Cortese, Patrizio Castagnola
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Membranes
Subjects:
Online Access:https://www.mdpi.com/2077-0375/11/3/199